NovaBay Pharmaceuticals, Inc. (NBY) P/E Ratio History
Deep ValueTrading at -0.6x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2009–2025
Loading P/E history...
P/E Ratio Analysis
As of October 3, 2026, NovaBay Pharmaceuticals, Inc. (NBY) trades at a price-to-earnings ratio of -0.6x, with a stock price of $1.47 and trailing twelve-month earnings per share of $0.55.
The current P/E is 100% below its 5-year average of 5557.1x. Over the past five years, NBY's P/E has ranged from a low of 10.7x to a high of 18080.6x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.2x, NBY trades at a 103% discount to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 190.0x.
Relative to the broader market, NBY trades at a notable discount to the S&P 500 median P/E of 24.5x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our NBY DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
NBY Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
NBY P/E vs Peers
Ophthalmology Therapies and Delivery peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $263M | 20.2 | 1.44Best | +13% | |
| $2B | 31.3 | 4.19 | +1883%Best | |
| $10B | 12.3Lowest | - | +190% | |
| $337B | 21.9 | 5.80 | +2% | |
| $10B | 26.0 | 8.23 | +7% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
NBY Historical P/E Data (2009–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | - | $6.40 | $0.60 | 10.7x | -100% |
| FY2025 Q2 | Jun 30 2025 | $2.90 | $0.22 | 13.2x | -100% |
| FY2010 Q2 | Jun 30 2010 | $329066.25 | $18.20 | 18080.6x | +225% |
| FY2010 Q1 | Mar 31 2010 | $336875.63 | $51.63 | 6524.8x | +17% |
| FY2009 Q4 | - | $315438.09 | $99.94 | 3156.3x | -43% |
Average P/E for displayed period: 5557.1x
NBY Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
17+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NBY — Frequently Asked Questions
Quick answers to the most common questions about buying NBY stock.
What is NBY's P/E ratio?
NovaBay Pharmaceuticals, Inc. (NBY) trailing twelve-month P/E ratio is -0.6x, based on TTM diluted EPS of $0.55. The 5-year average P/E is 5557.1x and the historical range spans 10.7x to 18080.6x.
Is NBY stock overvalued or undervalued?
NBY trades at -0.6x P/E, below its 5-year average of 5557.1x. At the 0th percentile of its historical range (10.7x–18080.6x), the stock is priced at a discount to its own history.
Is NBY stock expensive?
No, NBY is not expensive on a historical basis. The current P/E of -0.6x is below the 5-year average of 5557.1x and sits at the 0th percentile of its valuation range.
What is NBY's historical P/E range?
Over the past 5 years, NBY's P/E ratio has ranged from 10.7x to 18080.6x, with a median of 3156.3x and an average of 5557.1x. The current P/E of -0.6x places the stock at the 0th percentile of this range. Full historical data spans 2009–2025.
How does NBY's P/E compare to the S&P 500?
NBY trades at -0.6x P/E versus the S&P 500 median of 24.5x. The 102% discount to the market suggests lower growth expectations or perceived higher risk.
How does NBY's valuation compare to Healthcare peers?
NovaBay Pharmaceuticals, Inc. P/E of -0.6x compares to the Healthcare sector median of 23.2x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is NBY's PEG ratio?
NBY PEG ratio is N/A, based on a P/E of -0.6x and EPS growth of 98.2%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is NBY's earnings yield?
NBY earnings yield is N/A, the inverse of its -0.6x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.